Bio Pharma Dive
DECEMBER 17, 2024
Phase 2 results in inflammatory bowel disease hinted the therapy could be more potent than similar medicines from Merck and Roche, each of which were acquired in multibillion-dollar deals.
Pharmaceutical Technology
DECEMBER 18, 2024
Abera and Orexo have entered a partnership to develop and test the powder formulations of the formers vaccine candidates.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AuroBlog - Aurous Healthcare Clinical Trials blog
DECEMBER 18, 2024
People with missing teeth may be able to grow new ones, say Japanese dentists testing a pioneering drug they hope will offer an alternative to dentures and implants.
Worldwide Clinical Trials
DECEMBER 19, 2024
At the recent World Orphan Drug Congresses (WODC) in Europe and the United States, Worldwide Clinical Trials Derek Ansel , Vice President, Therapeutic Strategy Lead, Rare Disease, facilitated roundtable discussions to explore the operational challenges and ethical barriers surrounding genetic testing. While the agenda remained the same across both events, the conversations revealed key regional distinctions and global perspectives on how genetic testing, ethics, and operational challenges are ad
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharma Mirror
DECEMBER 16, 2024
CPHI Milan the worlds largest pharma event hosted last month in Milan saw a new record attendance of 59,000 pharma executives buoyed by returning confidence and increased deal-making on site. The post Pharma prepares for CDMO growth in 2025 as CPHI Milan reports record attendance appeared first on Pharma Mirror Magazine.
Bio Pharma Dive
DECEMBER 17, 2024
An FDA approval of Merck’s drug clesrovimab by June would give physicians another option for protecting newborns from respiratory syncytial virus.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
AuroBlog - Aurous Healthcare Clinical Trials blog
DECEMBER 15, 2024
The human body can survive without food for some time before starvation risks causing significant harm to the body.
Rethinking Clinical Trials
DECEMBER 18, 2024
Speaker Gbenga Ogedegbe, MD, MPH, FACP Dr. Adolph & Margaret Berger Professor of Population Health NYU Grossman School of Medicine Director, Institute for Excellence in Health Equity (IEHE) NYU Langone Health Slides Keywords Hypertension; Racial Disparities; Case Management; Telemonitoring Key Points There are significant racial disparities when it comes to stroke outcomes in the U.S., with Black and Hispanic populations experiencing poorer outcomes than Caucasian
Fierce Pharma
DECEMBER 17, 2024
Johnson & Johnson has received coal in its stocking from the FDA as manufacturing issues have tripped up the companys attempt to gain approval of its subcutaneous version of lung cancer drug R | The FDA has sent complete response letters to Johnson & Johnson and AstraZeneca, rejecting J&J's application for subcutaneous Rybrevant and AZ's bid for a full approval of Andexxa.
Bio Pharma Dive
DECEMBER 20, 2024
Novo shares lost nearly a quarter of their value after an experimental combination treatment called cagrisema fell short of the bar set by executives.
Pharmaceutical Technology
DECEMBER 20, 2024
Novo Nordisk has announced positive results from its Phase III trial of CagriSema but fell short of a previously promised 25% weight loss.
AuroBlog - Aurous Healthcare Clinical Trials blog
DECEMBER 16, 2024
Children with attention deficit hyperactivity disorder ( ADHD) do not have a behavioural disorder, nor are they lazy, or lacking in manners and boundaries. Their brains mature in a different way, with different patterns of neurological activity and a number of neurochemical differences. For this reason, ADHD is considered to be a neurodevelopmental disorder.
Rethinking Clinical Trials
DECEMBER 17, 2024
December 8, 2024 : The NIH Pragmatic Trials Collaboratory hosted a workshop at AcademyHealth's 17th Annual Conference on the Science of Dissemination and Implementation in Health. The workshop introduced concepts in the design, conduct, and implementation of pragmatic clinical trials embedded in healthcare systems, with a focus on methods relevant to health services researchers.
Medical Xpress
DECEMBER 20, 2024
UAB research has characterized in detail how polymer-based commercial tea bags release millions of nanoplastics and microplastics when infused. The study shows for the first time the capacity of these particles to be absorbed by human intestinal cells, and are thus able to reach the bloodstream and spread throughout the body.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Bio Pharma Dive
DECEMBER 19, 2024
The FDA’s decision will close a lucrative market opportunity for compounding pharmacies, although the agency will give a limited grace period before taking any enforcement actions.
Pharmaceutical Technology
DECEMBER 20, 2024
The US Food and Drug Administration (FDA) has stood by an earlier decision confirming that the tirzepatide shortage is over.
XTalks
DECEMBER 18, 2024
The US Food and Drug Administration (FDA) has granted approval to Checkpoint Therapeutics PD-L1 inhibitor Unloxcyt (cosibelimab-ipdl) for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) in patients who cannot be cured with surgery or radiation therapy. The approval marks the first product approval for the Massachusetts-based biotech and the first approved anti-programmed death-ligand 1 (PD-L1) treatment for advanced cSCC. cSCC is the second most common fo
Rethinking Clinical Trials
DECEMBER 16, 2024
A new study snapshot and updated ethics and regulatory documentation are now available for the I CAN DO Surgical ACP trial. As part of the study’s transition from the planning phase to the implementation phase this fall, the investigators reviewed and updated the minutes of their initial consultation with the Ethics and Regulatory Core. Read the updated ethics and regulatory documentation See the study snapshot I CAN DO Surgical ACP, an NIH Collaboratory Trial, is testing a system-based ap
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Fierce Pharma
DECEMBER 16, 2024
Another checkpoint inhibitor has entered the fray, as Checkpoint Therapeutics has passed the FDAs checkpoint with its PD-L1 inhibitor cosibelimab. | Another checkpoint inhibitor has entered the fray, as Checkpoint Therapeutics has passed the FDAs checkpoint with its PD-L1 inhibitor cosibelimab.
Bio Pharma Dive
DECEMBER 16, 2024
The company is scrapping two drugs aimed at targets called TIGIT and LAG-3, both of which were in the middle of Phase 3 testing.
Pharmaceutical Technology
DECEMBER 20, 2024
Astellas Pharma and Sangamo have signed a licence agreement for neurotropic adeno-associated virus (AAV) capsid, STAC-BBB.
pharmaphorum
DECEMBER 19, 2024
At its third attempt, Mesoblast has secured FDA approval for the first-ever mesenchymal stem cell (MSC) therapy, Ryoncil for acute GvHD in children.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Medical Xpress
DECEMBER 20, 2024
A research team led by Prof. Seung-Kyun Kang from the Department of Materials Science and Engineering at Seoul National University has developed a strain sensor with record-breaking sensitivity in collaboration with researchers from Dankook University, Ajou University, and Purdue University.
Fierce Pharma
DECEMBER 17, 2024
Its not a new question, but it is one that is gaining increased traction: Is there a link between Novo Nordisks diabetes superstar Ozempic and blindness? | After the recent release of two independent studies from the University of Southern Denmark suggested the use of Ozempic increases patients' chances of developing a rare eye disorder, the Danish Medicines Agency has asked European officials to investigate.
Bio Pharma Dive
DECEMBER 18, 2024
News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen as likely buyout targets.
Pharmaceutical Technology
DECEMBER 17, 2024
The two-day event included talks on subjects ranging from how to best utilise AI to how to build a stable CRO.
Advertiser: FourKites
A research study conducted by The Journal of Commerce and FourKites surveyed hundreds of international shippers, exploring how their usage of global supply chain visibility technology has evolved since the onset of global disruptions caused by COVID-19. For international shippers, ocean freight visibility has evolved from optional to essential and satisfaction with visibility varies greatly depending on how it is obtained and delivered.
pharmaphorum
DECEMBER 18, 2024
The FDA has started a review of MSD's RSV antibody clesrovimab, a potential rival to Beyfortus, with a verdict due in the middle of next year
Medical Xpress
DECEMBER 20, 2024
Human norovirus, a positive-strand RNA virus that is the leading cause of viral gastroenteritis accounting for an estimated 685 million cases and approximately 212,000 deaths globally per year, has no approved vaccines or antivirals.
AuroBlog - Aurous Healthcare Clinical Trials blog
DECEMBER 18, 2024
India needs new drugs, vaccines, and improve infection control practices to thwart antimicrobial resistance (AMR). From an India and global perspective, the recent advances in AMR treatment are bacteriophage therapy, nanotechnology, immunotherapies, among others. According to Dr Prabhu Vinayagam, medical advisor, Orchid AMS, a division of Orchid Pharma, the latest developments are novel antimicrobial agents.
Bio Pharma Dive
DECEMBER 19, 2024
An startup formed by KdT Ventures intends to test the drug, which was once licensed to Merck and evaluated in multiple metabolic disorders, for an unspecified rare conditon.
Expert insights. Personalized for you.
232 
Let's personalize your content